Capital International Sarl Has $28.77 Million Stake in Amgen Inc. $AMGN

Capital International Sarl decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 29.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 87,886 shares of the medical research company’s stock after selling 37,234 shares during the period. Capital International Sarl’s holdings in Amgen were worth $28,766,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new position in Amgen in the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC lifted its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMGN. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. Guggenheim dropped their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Finally, Rothschild & Co Redburn raised their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $353.81.

Amgen Stock Up 1.2%

Shares of Amgen stock opened at $349.58 on Friday. The business’s 50 day simple moving average is $341.35 and its 200 day simple moving average is $345.47. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The firm has a market cap of $188.67 billion, a PE ratio of 24.33, a P/E/G ratio of 3.51 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the firm earned $4.90 EPS. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.